REGN · Regeneron Pharmaceuticals, Inc.
$805.02
-1.72% last session
End-of-day data · close of 2026-10-23
Market cap
$83B
Enterprise value
$75B
Trailing P/E
19.9
Forward P/E
12.8
Dividend yield
0.0%
Beta
0.15
Avg volume
1M
Employees
15K
Daily Change %
-1.72%
5 Days Change
3.59%
10 Days Change
8.76%
30 Days Change
2.15%
60 Days Change
-1.14%
Month to Day Change
11.47%
Year to Day Change
6.53%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — REGN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-21
Latest call per bank · past 12 months
UBS
Buy$978
+21.5% vs priceRBC Capital
Sector Perform$810
+0.6% vs priceMorgan Stanley
Equal-Weight$779
-3.2% vs priceJP Morgan
Overweight$950
+18.0% vs priceJefferies
Buy$930
+15.5% vs priceHSBC
Buy$920
+14.3% vs priceCitigroup
Neutral$740
-8.1% vs priceWells Fargo
Equal-Weight$750
-6.8% vs priceBarclays
Overweight$917
+13.9% vs priceBank of America
Buy$860
+6.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | TD Cowen | Maintains | Buy | $960 → $980 |
| 2026-10-19 | Piper Sandler | Maintains | Overweight | $854 → $865 |
| 2026-10-15 | UBS | Upgrade | Neutral → Buy | $660 → $978 |
| 2026-10-08 | RBC Capital | Maintains | Sector Perform | $737 → $810 |
| 2026-10-07 | Truist Securities | Maintains | Buy | $772 → $780 |
| 2026-10-07 | Morgan Stanley | Maintains | Equal-Weight | $758 → $779 |
| 2026-10-06 | JP Morgan | Maintains | Overweight | $900 → $950 |
| 2026-10-01 | Jefferies | Maintains | Buy | $870 → $930 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 58 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 1.7% above the 50-day MA ($791.33).
- bullish: Price vs 200-day MA: Trading 9.6% above the 200-day MA ($734.73).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+7.32) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($572.75) and high ($852.03).
REGN Price Chart
Loading chart for REGN…
Fundamentals
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
GMAB
Genmab A/S
$27B 29.9% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.